Literature DB >> 1924851

Dose fractionation and tumour repopulation in radiotherapy for bladder cancer.

B Maciejewski1, S Majewski.   

Abstract

Local control of the 77 transitional cell carcinoma of the bladder was analysed with respect to total dose after normalization for variations in fraction size and to overall treatment time. For the TCD50 of 63.3 Gy protraction of overall treatment time from 40 to 55 days average gave the decrease in local control rate from 50% to about 5%. The decrease in local tumour control with extension of overall treatment time likely reflects accelerated tumour repopulation during the treatment. To determine the time onset of the accelerated tumour clonogen repopulation, data taken from the literature were analysed. Results show that on average tumour clonogen repopulation in transitional cell cancer of the bladder accelerates after a lag period of about 5-6 weeks after the start of treatment and that a dose increment of 0.36 Gy per day is required to compensate for this repopulation. Such a dose increment is consistent with about 5-8 day clonogen doubling time. It suggests that overall treatment time is an important factor in the dose fractionation and protraction of time may have a significant impact on treatment outcome. Thus, radiotherapy for bladder cancer should be completed as soon as possible and total dose for high probability of local tumour control should consequently be delivered in more than 5 fractions per week.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1924851     DOI: 10.1016/0167-8140(91)90033-d

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

1.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

Review 2.  Linear quadratic and tumour control probability modelling in external beam radiotherapy.

Authors:  S F C O'Rourke; H McAneney; T Hillen
Journal:  J Math Biol       Date:  2008-09-30       Impact factor: 2.259

3.  Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Skóra; Bogumiła Szyszka-Charewicz; Jerzy Jakubowicz
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

4.  Hypofractionated palliative radiotherapy for bladder cancer.

Authors:  Piet Dirix; Sofie Vingerhoedt; Steven Joniau; Ben Van Cleynenbreugel; Karin Haustermans
Journal:  Support Care Cancer       Date:  2015-05-16       Impact factor: 3.603

Review 5.  Cell death-stimulated cell proliferation: a tissue regeneration mechanism usurped by tumors during radiotherapy.

Authors:  Mary A Zimmerman; Qian Huang; Fang Li; Xinjiang Liu; Chuan-Yuan Li
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

Review 6.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

7.  α3β1 integrin promotes radiation-induced migration of meningioma cells.

Authors:  Venkateswara Rao Gogineni; Arun Kumar Nalla; Reshu Gupta; Meena Gujrati; Jeffrey D Klopfenstein; Sanjeeva Mohanam; Jasti S Rao
Journal:  Int J Oncol       Date:  2011-03-29       Impact factor: 5.650

8.  Pattern of failure in bladder cancer patients treated with radical cystectomy: rationale for adjuvant radiotherapy.

Authors:  Yong Bae Kim; Sung Joon Hong; Seung Cheol Yang; Jae Ho Cho; Young Deuk Choi; Gwi Eon Kim; Koon Ho Rha; Woong Kyu Han; Nam Hoon Cho; Young Taek Oh
Journal:  J Korean Med Sci       Date:  2010-05-24       Impact factor: 2.153

9.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

Review 10.  Combined chemotherapy and external beam radiotherapy for transitional cell carcinoma of the bladder.

Authors:  Ronald D Ennis
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.